Statins do more than just lower cholesterol

Lancet

Volumn 348, Issue 9034, 1996, Pages 1079-1082

  Vaughan, Carl J ^b   Murphy, Michael B ^b   Buckley, Brendan M ^a  

^a BON SECOURS HOSPITAL   (Ireland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; STATIN;

ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CORONARY ARTERY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; PRIORITY JOURNAL; THROMBOSIS;

EID: 0000306390     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)05190-2     Document Type: Note

References (29)

1. 1 Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
2. 2 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301-07.
3. 3 MAAS investigators. Effect of Simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633-38.
4. 4 Buchwald H, Campos CT, Boen JR, et al. Disease-free intervals after partial ilial bypass in patients with coronary heart disease and hypercholesterolaemia: report from the program on the surgical control of the hyperlipidemias (POSCH). J Am Coll Cardiol 1995; 26: 351-57.
5. 5 Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 1993; 87: 1781-91.
6. 6 Gerrity RG. The role of the monocyte in atherogenesis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol 1981; 103: 181-90.
7. 7 Ross R, Raines EW, Bowen-Pope DF. The biology of platelet-derived growth factor. Cell 1986; 46: 155-69.
8. 8 Henney AM, Wakeley PR, Davies MJ, et al. Location of stromelysin gene in atherosclerotic plaques using in situ hybridisation. Proc Natl Acad Sci 1991; 88: 8154-58.
9. 9 Keidar S, Aviram M, Maor I, Oiknine J, Brook JG. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies. Br J Clin Pharmacol 1994; 38: 513-19.
10. 10 McPherson R, Tsoukas C, Baines MG, et al. Effects of lovastatin on natural killer cell function and other immunological parameters in man. J Clin Immunol 1993; 13: 439-44.
11. 11 Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-27.
12. 12 Grandaliano G, Biswas P, Choudhury GG, Abboud HE. Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 1993; 44: 503-08.
13. 13 Rogler G, Lackner KJ, Schmitz G. Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro. Am J Cardiol 1995; 76: 114A-16A.
14. 14 Munro E, Patel M, Chan P, et al. Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis. Eur J Clin Invest 1994; 24: 766-72.
15. 15 Hidaka Y, Eda T, Yonemoto M, Kamei T. Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733). Atherosclerosis 1992; 95: 87-94.
16. 16 Yeung AC, Vekshtein VI, Krantz DS, et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med 1991; 325: 1551-56.
17. 17 Vita JA, Treasure CB, Yeung AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation 1992; 85: 1390-97.
18. 18 Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519-24.
19. 19 Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-87.
20. 20 Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A-25A.
21. 21 Hayoz D, Weber R, Rutschmann B, et al. Postischemic blood flow response in hypercholesterolemic patients. Hypertension 1993; 26: 497-502.
22. 22 Straznicky NE, Howes LG, Lam W, Louis WJ. Effects of pravastatin on cardiovascular reactivity to norepinephrine and angiotensin II in patients with hypercholesterolemia and systemic hypertension. Am J Cardiol 1995; 75: 582-86.
23. 23 Badimon JJ, Badimon L, Turitto VT, Fuster V. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels: in vivo study in the rabbit model. ArteriosclerThromb 1991; 11: 395-402.
24. 24 DiMinno G, Silver MJ, Cerbone AM, Rainone A, Postiglione A, Mancini M. Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis 1986; 6: 203-11.
25. 25 Mayer J, Eller T, Brauer P, et al. Effects of long-term treatment with lovastatin on the clotting system and blood platelets. Ann Hematol 1992; 64: 196-201.
26. 26 Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D. Hyperlipidaemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172-77.
27. 27 Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. ArteriosclerThromb Vasc Biol 1995; 15: 247-51.
28. 2+ and membrane dynamics in patients with hypercholesterolemia. Effects of pravastatin. Arterioscler Thromb Vasc Biol 1995; 15: 759-64.
29. 29 Wada H, Mori Y, Kaneko T, et al. Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993; 44: 112-16.